» Articles » PMID: 29562241

Altered Metabolism Distinguishes High-risk from Stable Carotid Atherosclerotic Plaques

Abstract

Aims: Identification and treatment of the rupture prone atherosclerotic plaque remains a challenge for reducing the burden of cardiovascular disease. The interconnection of metabolic and inflammatory processes in rupture prone plaques is poorly understood. Herein, we investigate associations between metabolite profiles, inflammatory mediators and vulnerability in carotid atherosclerotic plaques.

Methods And Results: We collected 159 carotid plaques from patients undergoing endarterectomy and measured 165 different metabolites in a targeted metabolomics approach. We identified a metabolite profile in carotid plaques that associated with histologically evaluated vulnerability and inflammatory mediators, as well as presence of symptoms in patients. The distinct metabolite profiles identified in high-risk and stable plaques were in line with different transcription levels of metabolic enzymes in the two groups, suggesting an altered metabolism in high-risk plaques. The altered metabolic signature in high-risk plaques was consistent with a change to increased glycolysis, elevated amino acid utilization and decreased fatty acid oxidation, similar to what is found in activated leucocytes and cancer cells.

Conclusion: These results highlight a possible key role of cellular metabolism to support inflammation and a high-risk phenotype of atherosclerotic plaques. Targeting the metabolism of atherosclerotic plaques with novel metabolic radiotracers or inhibitors might therefore be valid future approaches to identify and treat the high-risk atherosclerotic plaque.

Citing Articles

An atypical atherogenic chemokine that promotes advanced atherosclerosis and hepatic lipogenesis.

El Bounkari O, Zan C, Yang B, Ebert S, Wagner J, Bugar E Nat Commun. 2025; 16(1):2297.

PMID: 40055309 PMC: 11889166. DOI: 10.1038/s41467-025-57540-z.


Apolipoprotein B-containing lipoproteins in atherogenesis.

Boren J, Packard C, Binder C Nat Rev Cardiol. 2025; .

PMID: 39743565 DOI: 10.1038/s41569-024-01111-0.


Interleukin-6 and thyroid-stimulating hormone index predict plaque stability in carotid artery stenosis: analyses by lasso-logistic regression.

Zhigao L, Jiabo Q, Lei Z, Tong Q Front Cardiovasc Med. 2024; 11:1484273.

PMID: 39717442 PMC: 11663930. DOI: 10.3389/fcvm.2024.1484273.


TEAD1-Mediated Trans-Differentiation of Vascular Smooth Muscle Cells into Fibroblast-Like Cells Contributes to the Stabilization and Repair of Disrupted Atherosclerotic Plaques.

Zhai M, Lei Z, Shi Y, Shi J, Zeng Y, Gong S Adv Sci (Weinh). 2024; 12(5):e2407408.

PMID: 39665254 PMC: 11791998. DOI: 10.1002/advs.202407408.


Dysregulation of MMP2-dependent TGF-ß2 activation impairs fibrous cap formation in type 2 diabetes-associated atherosclerosis.

Singh P, Sun J, Cavalera M, Al-Sharify D, Matthes F, Barghouth M Nat Commun. 2024; 15(1):10464.

PMID: 39653743 PMC: 11628557. DOI: 10.1038/s41467-024-50753-8.


References
1.
McCoin C, Knotts T, Adams S . Acylcarnitines--old actors auditioning for new roles in metabolic physiology. Nat Rev Endocrinol. 2015; 11(10):617-25. PMC: 4966159. DOI: 10.1038/nrendo.2015.129. View

2.
Cramer T, Yamanishi Y, Clausen B, Forster I, Pawlinski R, Mackman N . HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell. 2003; 112(5):645-57. PMC: 4480774. DOI: 10.1016/s0092-8674(03)00154-5. View

3.
Joseph P, Tawakol A . Imaging atherosclerosis with positron emission tomography. Eur Heart J. 2016; 37(39):2974-2980. DOI: 10.1093/eurheartj/ehw147. View

4.
Vorkas P, Shalhoub J, Isaac G, Want E, Nicholson J, Holmes E . Metabolic phenotyping of atherosclerotic plaques reveals latent associations between free cholesterol and ceramide metabolism in atherogenesis. J Proteome Res. 2015; 14(3):1389-99. DOI: 10.1021/pr5009898. View

5.
Nilsson J . Atherosclerotic plaque vulnerability in the statin era. Eur Heart J. 2017; 38(21):1638-1644. DOI: 10.1093/eurheartj/ehx143. View